Roots Analysis

 The report presents a comprehensive study of the current and future potential of automated sampling systems . Due to increasing demand for biologics and strict regulatory standards, the biopharmaceutical industry has turned to automated sampling methods that provide reliable systems for the direct transfer of bioprocess samples from bioreactors to analyzers while maintaining process sterility and integrity. In addition, it provides a detailed discussion of the likely opportunities for actors working in this field over the next decade. Amongst other elements, the report includes: A detailed assessment of the current market landscape of automatic sampling systems and their manufacturers. A competitiveness analysis of automatic sampling systems manufacturers. Elaborate profiles of prominent players engaged in the manufacturing of automatic sampling systems ( shortlisted based on company size ). A detailed market landscape of automatic sample collection / preparation systems and their...

 Aptamers have gained significant momentum over the past decade. It’s worth noting that in 2005, Macugen became the first and only aptamer drug approved by the USFDA for the treatment of age-related macular degeneration (AMD). More than 15 million people have been reported to have AMD in the US alone, with 200,000 cases per year across North America. This indicates a large unmet patient need and paves the way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid development in the domain, which is attributed to various factors such as the number of clinical trials, increased awareness of the advantages that aptamers offer over antibodies. It is an increase in investment in pharmaceutical research and development, along with the increasing prevalence of chronic and rare diseases have contributed to an increased demand for therapeutic and diagnostic solutions based on aptamers. Over the past three decades, since the inv...

Recent advances in information technology and biomedical science have enabled the development of several versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions. According to experts,  digital therapeutic solutions  are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions have seen a surge in adoption amid the COVID-19 pandemic. Roots Analysis has the addition of "Digital Health Market: Focus on Digital Therapy (2nd Edition), 2020-2030 (based on solution type (software solution, gaming solution and combined solution), type of therapy (curative and preventive), and purpose of solution (drug replacement and drug augmentation) in your offer list. The report includes input from key ind...

The market for Companion Diagnostics Development Services is valued at over USD 800 million; Roots Analysis projects growth at an annualized rate of ~5% through 2030. A record number of personalized therapeutic products have been approved in the US in recent years, creating an urgent need for companion diagnostics and prompting many drug developers to actively seek external support and expertise. It is estimated that around 80% of innovative companies rely on external companion diagnostics developers, mainly due to the lack of required in-house expertise. On the other hand, numerous contract service providers are offering a broad portfolio of diagnostic test/assay development services. Such companies are known for having extensive technical knowledge and experience in working with cutting-edge analytical tools and technologies. The report offers a comprehensive study of the current market landscape and offers an informed opinion on the likely adoptionof diagnostic development se...